Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1479)	4/20/2003 9:41:26 PM
From: quidditch	Respond to of 3044

"The FDA cannot really say no unless there are some undisclosed and very negative side-effects." And, just to review the bidding, what are the potential markets for MM and solid tumors, the latter being the large pot in the center of the table? $250-$300m for MM if adopted as a standard treatment. And, I know I asked this several months ago, in terms of method of action, what does the board think the differences are in bio-chemical determinants between MM and solid tumors? Is it likely to be differences in cancer cell sites, depending on whether its CC, hepatic or LC, or an entirely different method of action to suppress bad cell formation/promote cell death? Do Levin and crew have a clue if these are in the same ball park or a shot in the dark? I'm aware that this is reducing the discussion to the LCD, but it will help me catch on toa conceptual approach. quid

To: Icebrg who wrote (1479)	4/22/2003 5:35:09 PM
From: Icebrg	Read Replies (2) \| Respond to of 3044

April 22, 2003 MILLENNIUM PHARMACEUTICALS INC (MLNM) form 8-K Item 5. Other Events and Regulation FD Disclosure. On April 22, 2003, Aventis Pharmaceuticals, Inc. provided to Millennium Pharmaceuticals, Inc. notice of exercise of its option to terminate the three to five-year Technology Transfer Agreement between Millennium and Aventis dated June 22, 2000, effective on the third anniversary of the Agreement, July 21, 2003. Pursuant to the terms of the Agreement, upon providing this notice to Millennium, Aventis paid to Millennium $40,000,000 in consideration for future use of certain Millennium technology transferred to Aventis prior to the termination date, resulting in a total of $160,000,000 paid to Millennium under the Agreement during its term. Termination of the Technology Transfer Agreement has no effect upon the existing five-year Collaboration and License Agreement dated June 22, 2000 between Aventis and Millennium for the joint discovery, development and commercialization of drugs for the treatment of specified inflammatory diseases.